Amneal Pharmaceuticals Inc(AMRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 44.74 | EPS (ttm) | 0.48 | Insider Own | 55.02% | Shs Outstand | 319.3M | Perf Week | 8.06% |
| Market Cap | 6.85B | Forward P/E | 17.81 | EPS next Y | 17.17% | Insider Trans | -0.25% | Shs Float | 143.6M | Perf Month | 4.59% |
| Enterprise Value | 9.59B | PEG | 0.87 | EPS next Q | 0.24 | Inst Own | 48.28% | Short Float | 9.79% | Perf Quarter | 12.25% |
| Income | 0.16B | P/S | 2.2 | EPS this Y | 23.76% | Inst Trans | 1.28% | Short Ratio | 5.15 | Perf Half Y | 68.35% |
| Sales | 3.12B | P/B | 207.31 | EPS next 5Y | 20.48% | ROA | 4.37% | Short Interest | 14.07M | Perf YTD | 70.16% |
| Book/sh | 0.1 | P/C | 50.24 | EPS past 3/5Y | - -18.36% | ROE | - | 52W High | 1.25% ($21.17) | Perf Year | 109.17% |
| Cash/sh | 0.43 | P/FCF | 84.41 | Sales past 3/5Y | 10.92% 8.66% | ROIC | 5.82% | 52W Low | 114.61% ($9.99) | Perf 3Y | 468.7% |
| Dividend Est. | - | EV/EBITDA | 14.28 | EPS Y/Y TTM | 4917.17% | Gross Margin | 39.32% | Volatility(W/M) | 2.6% 3.14% | Perf 5Y | 301.5% |
| Dividend TTM | - | EV/Sales | 3.07 | Sales Y/Y TTM | 9.28% | Oper. Margin | 15.3% | ATR (14) | 0.66 | Perf 10Y | -0.05% |
| Dividend Ex-Date | - | Quick Ratio | 1.44 | EPS Q/Q | 152.81% | Profit Margin | 5.05% | RSI (14) | 69.26 | Recom | 1.12 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.2 | Sales Q/Q | 9.89% | SMA20 | 7.2% ($20) | Beta | 1.26 | Target Price | $23 |
| Payout | - | Debt/Eq | 84.55 | Earnings | 2026/11/3 | SMA50 | 13.29% ($18.92) | Rel Volume | 1.06 | Prev Close | $21.02 |
| Employees | 8500 | LT Debt/Eq | 80.87 | EPS/Sales Surpr. | 34.83% 3.64% | SMA200 | 37.28% ($15.62) | Avg Volume(3M) | 2.73M | Price | $21.44 |
| IPO | 1995/12/19 | Option/Short | Yes/Yes | Trades | 15924 | Volume | 2,888,118 | Change | 2% |
💊 A diversified U.S. pharmaceutical company covering generic drugs, specialty medicines, and biosimilars. It operates a broad product portfolio across generic medications, specialty drugs in central nervous system and endocrinology, biosimilars, and pharmaceutical distribution. The company is a diversified pharmaceutical player combining generics and specialty pharmaceuticals.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded about as much as usual. That is 106% of its average volume.
Next earnings report: November 3
6 days to go.
AMRX makes money exceptionally well
Of every $100 in sales, $15.30 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +23.8% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,781. Peers typically go for $1,485. Compared with its own 1-year average, it is 18% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +301.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 48.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #12 of 83 in the industry
Based on market cap of $7B.
ALKS#10 Alkermes plc $7B PER 115.1 
KNSA#11 Kiniksa Pharmaceuticals International Plc $7B PER 90.7 AMRX#12 Amneal Pharmaceuticals Inc $7B PER 44.7 
LNTH#13 Lantheus Holdings Inc $7B PER 24.2 
HIMS#14 Hims & Hers Health Inc $7B PER - 
FAQ
What kind of company is AMRX?
AMRX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AMRX?
The market cap of AMRX is approximately $6.8B, ranking 1,148 within its sector.
What is the P/E ratio of AMRX?
AMRX has a P/E ratio of approximately 44.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for AMRX?
AMRX has recorded a 52-week high of $21.17 and a low of $9.99.
